基本信息
浏览量:184
职业迁徙
个人简介
I completed my PhD in cancer signalling at the Peter MacCallum Cancer Institute in Melbourne. After my post-doctoral training in the Department of Pharmacology (UoM), I joined the CRC-Chronic Inflammatory Diseases as a Project Leader where I turned my attention to translational research involving validation of lead targets in clinical cohorts based at RMH. In 2014, I was awarded an ARC Future Fellowship and transitioned my laboratory to the RMIT University to head the Airways Inflammation Research (AIR) group.
My research team has driven translational research efforts leading to the discovery of COPD biomarkers that predict severity of acute exacerbations. I continue to focus on how biomarkers transition to pathogenic mediators in the context of chronic inflammatory lung conditions including COPD, asthma and lung cancer. My team has made internationally recognised contributions to the field of resolution of inflammation in both complex respiratory infection and the chronic lung disease setting. My team has demonstrated that pro-resolving mediators such as Lipoxins and Resolvins are very effective in switching off persistent lung inflammation and improving pathogen clearance. I continue to work with clinical collaborators at the Royal Melbourne Hospital, Austin Health and St Vincent's hospital to drive this research towards clinical applications. More recently, I have focused on the inflammatory-resolution axis in lung cancer and developed biomarkers to guide use of novel therapies.
My research team has driven translational research efforts leading to the discovery of COPD biomarkers that predict severity of acute exacerbations. I continue to focus on how biomarkers transition to pathogenic mediators in the context of chronic inflammatory lung conditions including COPD, asthma and lung cancer. My team has made internationally recognised contributions to the field of resolution of inflammation in both complex respiratory infection and the chronic lung disease setting. My team has demonstrated that pro-resolving mediators such as Lipoxins and Resolvins are very effective in switching off persistent lung inflammation and improving pathogen clearance. I continue to work with clinical collaborators at the Royal Melbourne Hospital, Austin Health and St Vincent's hospital to drive this research towards clinical applications. More recently, I have focused on the inflammatory-resolution axis in lung cancer and developed biomarkers to guide use of novel therapies.
研究兴趣
论文共 242 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Nok Him Fung, Quynh Anh Nguyen,Catherine Owczarek,Nick Wilson, Nadeem Elahee Doomun,David De Souza,Kylie Quinn,Stavros Selemidis,Jonathan McQualter,Ross Vlahos,Hao Wang,Steven Bozinovski
Respiratory Researchno. 1 (2024): 1-14
Hao Wang,Kwok Ho Yip, Simon P. Keam,Ross Vlahos, Kristy Nichol,Peter Wark,John Toubia, Anita C. Kral, Goeurokhan Cildir,Harshita Pant,Timothy R. Hercus, Nick Wilson,
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYno. 3 (2024)
Madison Coward-Smith,Stella Liong,Osezua Oseghale,Jonathan R. Erlich,Mark A. Miles,Felicia Liong,Kurt Brassington,Steven Bozinovski,Ross Vlahos,Robert D. Brooks,Doug A. Brooks, John J. O'Leary,
FRONTIERS IN IMMUNOLOGY (2024): 1378610-1378610
The Journal of Allergy and Clinical Immunology (2023)
引用0浏览0引用
0
0
Brain, behavior, and immunity (2023): 292-307
Hao Wang,Kwok Ho Yip, Simon P Keam,Ross Vlahos,Kristy Nichol,Peter Wark,John Toubia, Anita C Kral,Gökhan Cildir,Harshita Pant,Timothy R Hercus,Nick Wilson,
Methods in molecular biology (Clifton, N.J.) (2023): 97-109
引用0浏览0WOS引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn